{
  "id": 2572785,
  "title": "What to Know About the CFO of Tempus AI's Latest Insider Transaction Filing",
  "url": "https://urgent.news/2026/08/22/what-to-know-about-the-cfo-of-tempus-ais-latest-insider-transaction",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-22T12:11:33.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/markets/stocks/articles/know-cfo-tempus-ais-latest-121133933.html"
  },
  "original_language": "en",
  "account": "Tempus AI's CFO, James William Rogers, sold 48,842 shares of the company's Class A Common Stock on August 18 and 19, as revealed in a recent SEC Form 4 filing. The transaction value, calculated using the SEC Form 4 weighted average sale price of $55.21, amounted to $2.85 million. The post-transaction value, based on the August 19 market close at $61.25, was $2.99 million. The sale was a non-discretionary transaction aimed at fulfilling tax withholding obligations arising from the vesting of restricted stock units. This action was executed under a pre-existing Rule 10b5-1 trading plan adopted on September 11, 2025, and does not signify a shift in the CFO's fundamental opinion on the company.\n\nFollowing the sale, James William Rogers now holds 106,000 shares, representing an insider ownership stake of approximately 0.06% of the company's outstanding equity. As of the August 19 transaction date, the stock's one-year total return stood at -16%. The transaction was conducted at a weighted-average price of $55.21 per share, while the stock closed at $61.25 on August 19.\n\nTempus AI operates in the healthcare information services sector with around 3,800 employees. The company reported trailing twelve-month revenue of $1.4 billion and experienced a net loss of $254.4 million. Tempus AI's market capitalization is currently valued at $10.7 billion. The company offers a technology-enabled laboratory services model that combines next-generation sequencing (NGS) testing with AI-driven analytics to provide actionable clinical insights to healthcare providers, focusing on oncology and precision medicine applications. The full-stack healthcare technology platform integrates clinician workflows with laboratory diagnostic capabilities.\n\nDespite the recent share sale, Tempus AI's long-term prospects remain positive. The company employs a technology-driven laboratory services model that differentiates it from competitors, with a proprietary multimodal data repository and closed-loop integration between clinician workflows and laboratory capabilities. This positions Tempus AI as a comprehensive solution provider in precision medicine, attracting significant market interest despite its current net losses. The CFO's sale appears to adhere to an established 10b5-1 plan structure, executed on both August 18 and 19.",
  "summary": null,
  "key_points": [
    "James William Rogers sold 48,842 shares of Tempus AI's Class A Common Stock on August 18-19.",
    "Sale valued at $2.85 million, with post-transaction value of $2.99 million.",
    "Rogers now owns 106,000 shares, representing 0.06% ownership of the company."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "What to Know About the CFO of Tempus AI's Latest Insider Transaction Filing",
        "url": "https://urgent.news/2026/08/22/what-to-know-about-the-cfo-of-tempus-ais-latest-insider-transaction-2577540",
        "published": "2026-08-22T11:51:33.000Z"
      },
      {
        "outlet": "Nasdaq Markets",
        "title": "What to Know About the CFO of Tempus AI's Latest Insider Transaction Filing",
        "url": "https://urgent.news/2026/08/22/what-to-know-about-the-cfo-of-tempus-ais-latest-insider-transaction-2579364",
        "published": "2026-08-22T12:11:33.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}